BRIEF published on 05/07/2024 at 17:50, 2 years 1 month ago L'Assemblée Générale 2024 d'Edenred marque l'approbation complète des résolutions et la bonne performance de l'entreprise Edenred Assemblée Générale Dividende ESG La Performance De L'entreprise
REGULATED PRESS RELEASE published on 05/07/2024 at 17:45, 2 years 1 month ago L’Assemblée générale 2024 d’Edenred approuve l’ensemble des résolutions L'Assemblée générale 2024 d’Edenred approuve l’ensemble des résolutions. Distribution d'un dividende de 1,10 euro par action, renouvellement de mandats et résultats financiers record en 2023 Edenred Résultats Financiers Assemblée Générale Dividende Resolutions
REGULATED PRESS RELEASE published on 05/07/2024 at 17:45, 2 years 1 month ago Edenred’s 2024 General Meeting approves all resolutions Edenred's 2024 General Meeting approves all resolutions, including dividend payment and board member renewals. Company highlights successful Beyond22-25 plan and record financial performance in 2023 Edenred Financial Performance Dividend Payment General Meeting Beyond22-25 Plan
BRIEF published on 05/03/2024 at 17:55, 2 years 1 month ago Edenred Announces Share Capital and Voting Rights as of April 2024 Edenred Autorité Des Marchés Financiers Share Capital Voting Rights French Commercial Code
BRIEF published on 05/03/2024 at 17:55, 2 years 1 month ago Déclaration du Nombre d'Actions et de Droits de Vote de Edenred au 30 Avril 2024 Edenred Droits De Vote Actions Information Réglementée Investisseurs
REGULATED PRESS RELEASE published on 05/03/2024 at 17:50, 2 years 1 month ago Disclosure of Share Capital and Voting Rights as of April 30, 2024 Edenred discloses share capital and voting rights per French regulations. As of April 30, 2024, shares outstanding are 249,588,059 with 250,668,932 exercisable voting rights Edenred Share Capital Voting Rights Investors French Regulations
REGULATED PRESS RELEASE published on 05/03/2024 at 17:50, 2 years 1 month ago Déclaration du nombre d’actions et droits de vote au 30 avril 2024 Edenred déclare le nombre d'actions et de droits de vote conformément à la réglementation financière. Toutes les informations sont disponibles sur edenred.com Edenred Droits De Vote Réglementation Financière Actions Investisseurs
BRIEF published on 04/19/2024 at 08:23, 2 years 2 months ago Edenred engage un mandat de rachat d'actions Edenred Investissement Rachat D'actions Bourse Réglementation Européenne
BRIEF published on 04/19/2024 at 08:23, 2 years 2 months ago Edenred Announces Share Buyback Agreement Edenred Shareholder Value Share Buyback Investment Services Provider EU Regulation No. 596/2014
REGULATED PRESS RELEASE published on 04/19/2024 at 08:18, 2 years 2 months ago Edenred: Mandat de rachat d’actions Edenred annonce la conclusion d'un mandat de rachat d'actions avec un PSI pour un montant maximal de 50 millions d'euros, en vue de racheter jusqu'à 300 millions d'euros d'actions d'ici mars 2027, conformément aux régulations en vigueur Edenred Assemblée Générale 2024 Mandat De Rachat D'actions PSI 300 Millions D'euros
Published on 06/26/2026 at 14:05, 2 hours 15 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 2 hours 20 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 3 hours 20 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 3 hours 35 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 15:30, 50 minutes ago JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 56 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 15:23, 57 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 07:00, 9 hours 20 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 9 hours 20 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
